portrait
Research groups
Pramila Rijal
DPhil
Senior Postdoctoral Scientist
Antibodies and vaccines against influenza virus
Antibodies and Vaccine Development Against Infectious Viruses
Dr Pramila Rijal obtained her Ph.D. from the University of Oxford in 2017, specialising in studying the human monoclonal antibody response to influenza and Ebola viruses following natural infection or vaccination. With more than ten years of dedicated research, she has demonstrated proficiency in both antibody and vaccine development for combating infectious diseases. Presently, her research takes centre stage on the influenza neuraminidase (NA) protein, where she applies her expertise in refining monoclonal antibodies in vitro, spearheads the development of NA-based nanoparticle vaccine for targeting potentially pandemic influenza viruses, and contributes significantly to the discovery of novel drugs targeting this essential viral protein.
Recent publications
-
A review of broadly protective monoclonal antibodies to treat Ebola virus disease.
Journal article
Rijal P. and Donnellan FR., (2023), Curr Opin Virol, 61
-
A rapid antibody screening haemagglutination test for predicting immunity to SARS-CoV-2 variants of concern.
Journal article
Ertesvåg NU. et al, (2022), Commun Med (Lond), 2
-
Two doses of SARS-CoV-2 vaccination induce more robust immune responses to emerging SARS-CoV-2 variants of concern than does natural infection.
Preprint
Skelly DT. et al, (2021)
-
Protective porcine influenza virus-specific monoclonal antibodies recognize similar haemagglutinin epitopes as humans.
Journal article
Holzer B. et al, (2021), PLoS Pathog, 17
-
Breadth and function of antibody response to acute SARS-CoV-2 infection in humans.
Journal article
Huang K-YA. et al, (2021), PLoS Pathog, 17